BIO vs KALV · rev $651.0M vs rev $13.7M
BIO (BIO) versus Kalvista Pharmaceuticals Inc (KALV) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. KALV currently screens at market cap $1.44B.
BIO currently screens at market cap $0. KALV currently screens at market cap $1.44B.
Not investment advice. Open the BIO and KALV stock pages for the full models.
Not investment advice.